

IMPORTANT: THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

Each of The Stock Exchange of Hong Kong Limited, Hong Kong Exchanges and Clearing Limited (“**HKEx**”), Hong Kong Securities Clearing Company Limited and the Securities and Futures Commission (the “**SFC**”) takes no responsibility for the contents of this Announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Announcement.

The Manager accepts full responsibility for the accuracy of the information contained in this Announcement as at the date of publication, and confirms, having made all reasonable enquiries, that to the best of its knowledge and belief, as at the date of publication, opinions expressed in this Announcement have been arrived at after due and careful consideration.

SFC authorisation is not a recommendation or an endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

ChinaAMC Global ETF Series (the “Trust”)

*(a Hong Kong umbrella unit trust authorized under
Section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)*

ChinaAMC Hang Seng Biotech ETF

HKD Counter Stock Code: 03069

RMB Counter Stock Code: 83069

USD Counter Stock Code: 09069

(the “Sub-Fund”)

Announcement Revisions to index methodology

Unless otherwise defined in this Announcement, capitalised terms used in this Announcement shall have the same meaning as defined in the prospectus of the Trust and the Sub-Fund (the “**Prospectus**”).

China Asset Management (Hong Kong) Limited (the “**Manager**”), the manager of the Sub-Fund, hereby announces that Hang Seng Indexes Company Limited (the “**Index Provider**”), being the index provider of Hang Seng Biotech Index (the “**Index**”), which is the underlying index of the Sub-Fund, has introduced a change to the index methodology of the Index (the “**Revised Methodology**”). The Revised Methodology will be applied in the index review for the period ending 31 December 2025, and the corresponding change will be effective on 9 March 2026 (the “**Effective Date**”).

1. Volatility screening requirement

The Revised Methodology will add a volatility screening requirement for non-constituent biotech companies with stock names ending with marker “B”. To be eligible for constituent selection, the 12-month historical volatility (i.e. standard deviation of the daily logarithmic return for the past 12 months to the data cut-off date) of such a security should not be greater

than three times the 12-month historical volatility of the Index. For a security with less than 1-month of listing history, historical volatility between its listing date and the last trading day of the month following the data cut-off date will be compared with the 12-month historical volatility of the Index as of the data cut-off date.

2. Impact on the Sub-Fund

The Manager confirms that (i) the above change will not amount to a material change to the Sub-Fund; (ii) there will be no material change or increase in the overall risk profile of the Sub-Fund as a result of the change; and (iii) there will be no material adverse impact on Unitholders' rights or interests (including changes that may limit Unitholders' ability in exercising their rights).

3. General

The updated Prospectus will be available on the Effective Date to reflect the change as described above and other miscellaneous updates, and will be uploaded on the Manager's website at www.chinaamc.com.hk (this website has not been reviewed by the SFC) and the HKEX's website at www.hkex.com.hk.

Investors who have any enquiries regarding the above may contact the Manager at 37/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong or our enquiry hotline at (852) 3406 8686 during office hours.

**China Asset Management (Hong Kong) Limited
as Manager of the Trust and the Sub-Fund
9 March 2026**